ConductScience.org, home
A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh
API referenceFor AI assistants

Trial · NCT01797029

Outcomes16

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 16 of 16

Download this page as JSON
TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYPercentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains).Through 7 to 9 months post-vaccinationpercentage of participantsNUMBER
SECONDARYSafety Profile of LAIV: Solicited and Unsolicited Local and Systemic ReactionsThrough one week post-vaccination
SECONDARYSafety Profile of LAIV: Immediate Reactions30 minutes post-vaccinationparticipantsNUMBER
SECONDARYSafety Profile of LAIV: Serious Adverse EventsThrough 7 to 9 months post-vaccination
SECONDARYSafety Profile of LAIV: Protocol Defined Wheezing IllnessThrough 7 to 9 months post-vaccination
SECONDARYPercentage of Participants With Symptomatic, Laboratory-confirmed, Influenza Virus Infection (All Strains)Through 7 to 9 months post-vaccination
SECONDARYThe Clinical Characteristics of Influenza, Including Influenza Co-infections With Other Bacterial and Viral Respiratory PathogensThrough 16 to 19 months post-vaccination
SECONDARYThe Viral Etiologies of Acute Respiratory and Febrile IllnessThrough 16 to 19 months post-vaccination
SECONDARYSafety Profile of LAIV: Serious Adverse EventsThrough 16 to 19 months post-vaccination
SECONDARYSafety Profile of LAIV: Protocol Defined Wheezing IllnessThrough 16 to 19 months post-vaccination
SECONDARYPercentage of Participants With Symptomatic, Laboratory-confirmed, Influenza Virus Infection (All Strains)Through 16 to 19 months post-vaccination
SECONDARYPercentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains).Through 16 to 19 months post-vaccination
OTHER_PRE_SPECIFIEDPercentage of Participants With Moderate to Severe, Laboratory-confirmed Influenza Virus Infection Among ChildrenThrough 7 to 9 months post-vaccination
OTHER_PRE_SPECIFIEDPercentage of Participants With Moderate to Severe, Laboratory-confirmed Influenza Virus Infection Among ChildrenThrough 16 to 19 months post-vaccination
OTHER_PRE_SPECIFIEDPercentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains) Among ChildrenFrom approx. 6 months to approximately 19 months post-vaccination
OTHER_PRE_SPECIFIEDPercentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (All Strains) Among ChildrenFrom approx. 6 months to approximately 19 months post-vaccination

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01797029/outcomes

API referenceFor AI assistants